Our Mission Statement
This is Photoshop's version of Loremer Ipsn gravida nibh vel velit auctoregorie sam alquet.Aenean sollicitudin, lorem quis bibendum auci elit consequat ipsutis sem nibh id elit.
Follow Us
Who We Are – Transcell
page-template,page-template-full-width,page-template-full-width-php,page,page-id-6668,mkd-core-1.0,highrise-ver-1.0,,mkd-smooth-page-transitions,mkd-ajax,mkd-grid-1300,mkd-blog-installed,mkd-header-vertical,mkd-sticky-header-on-scroll-up,mkd-default-mobile-header,mkd-sticky-up-mobile-header,mkd-dropdown-slide-from-bottom,mkd-dark-header,mkd-full-width-wide-menu,mkd-search-dropdown,mkd-side-menu-slide-from-right,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

Who We Are

Transcell Oncologics has dedicated team working on

  • Real time throughput screening of toolbox based novel complex compounds
  • Genomics of Indian cancer patients sourced cancer stem cells based platforms exposed to druggable molecules
  • Hunting for undruggable challenging targets in cancers for druggable molecules
  • Elucidating novel mechanistic pathways leading to known targets modulated by small molecules
  • Drug discovery from the insights of cancer genomics

As a stem cell based biotech company, we uniquely leverage our distinct insights from adult stem cells sourced from patients samples, donor samples, predictive stem cell technologies to discover the anti-cancer stem/cell properties, hunting for druggable molecules that selectively kill cancer stem cells. The data on human/patient based platforms/models, Genomics and Proteomics aid to advance our pipeline to clinical proof of concept and discovery of functional molecules. Access to all new nature inspired complex macrocyclic small molecules along with the wisdom derived from the stem cell technologies are our differentiating positioning in this space accelerating the process of drug discovery in Oncology.

R & D Team

S Dravida, PhD

S Dravida leads the team and collaborations responsible for discovering druggable formulations across therapeutic areas and platforms. Her role requires converging and executing both laboratory, clinical research programs across touch points.

Past Affiliations:

  • University of North Carolina, Ottawa Health Research Institute,
  • Center for Cellular and Molecular Biology, Hyderabad Eye Research Foundation.

Expertise: Adult stem cell technologies, Predictive platform development and screening, Primary cells, Tumorospheres, Low throughput and High throughput platform technologies, Cancer progenitor cells, Repository of patient sourced screening platforms, Cell based readouts, Drug discovery, pre-discovery process

S Dravida is the inventor of Transcell’s proprietary technologies and has authored or co-authored peer-reviewed research publications in the same domain of practice.

Raveendra Babu M, PhD

Past Affiliations:

  • Doctor of Philosophy (Ph.D.) 2010–2018
  • Centre for DNA Fingerprinting and Diagnostics (CDFD), Hyderabad

Expertise: Molecular biology, Biochemistry, Transformed cell lines, Cellular signalling, melanoma biology, Anti-cancer chemotherapeutics’ studies, Transduction,  Translational Research.

Vamshi Krishna Irlapati, PhD

Past Affiliations :

  • Dec, 2017 – May, 2018: Academic Consultant (Temporary), Dept. of Genetics and Biotechnology, Osmania University.
  • 2016-2017: Co-founder and manager of http://www.iscienceresearch.com
  • 2010-2016: Ph.D Biotechnology, Dr. Reddy’s Institute of Life Sciences, affiliated to University of Hyderabad, Hyderabad, India
  • 2009-2010: Research Trainee, Dr. Reddy’s Institute of Life Sciences, University of  Hyderabad, Hyderabad, India.
  • 2008-2009: Industrial Project Trainee, BCIL fellowship, sponsored by Department of Biotechnology, Jupiter Biosciences Pvt. Ltd, India.

Expertise: Mammalian cell culture, Protein kinase research, Recombinant DNA techniques, Protein expression and purification, RNA isolation and quantitative RT-PCR, Human cancer biopsy handling, Zebrafish as an in vivo model (basic skills and knowledge).

Toolbox Chemistry

Natural product-inspired 3D architectures, Bioactive natural products with sufficient complexity, Scalable synthesis processes, functionalized macrocyclic compounds with large surface area, first-in-class small molecules, next generation druggable for challenging targets, Scaffolds having indole- and tetrahydroquinoline-inspired alkaloids, benzofuran- and benzopuran-inspired polyphenolics.